Notably, although mTOR is hyperactive in VHL‐deficient 786‐O cells compared with that in Caki‐1 cells with wild‐type VHL expression, both RCC cell types showed similar sensitization to everolimus in the presence of MC‐4, indicating VHL‐independent phosphoinositide 3‐kinase /PKM2/mTOR signaling inhibition. This evidence concerns the gene MTOR and renal cell carcinoma.